SCAP and non-small cell lung carcinoma: This is consistent with our findings that enhanced SREBP-1/SCAP/FASN signaling is implicated in the reduced sensitivity of NSCLC cells to cisplatin therapy, and that the viability and stemness of these resistant NSCLC cells can be modulated through shRNA-mediated silencing of SREBP-1 or the introduction of exogenous hsa-miR-497-5p into cisplatin-resistant NSCLC cells.